title: Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
abstract: Telomere lengthening is one of the key events in most cancers, and depends largely on telomerase activation. Telomerase activation is a well-known phenomenon in gliomas; however, its mechanism remains obscure. In this study, we investigated the presence of mutations in the promoter of the telomerase reverse transcriptase (TERT) gene in a series of 546 gliomas. We found a high incidence of mutually exclusive mutations located at two hot spots, C228T and C250T, in all subtypes of gliomas (55 %). The frequency of mutation was particularly high among primary glioblastomas (70 %) and pure oligodendroglial tumors (74 %), while relatively low in diffuse astrocytomas and anaplastic astrocytomas (19 and 25 %, respectively). The expression level of TERT in tumors carrying those mutations was on average 6.1 times higher than that of wild-type tumors, indicating that the mutated promoter leads to upregulation of TERT. TERT promoter mutations were observed in almost all tumors harboring concurrent total 1p19q loss and IDH1/2 mutations (98 %). Otherwise TERT promoter mutations were mostly observed among IDH wild-type tumors. Most EGFR amplifications (92 %) were also associated with TERT promoter mutations. Our data indicate that mutation of the TERT promoter is one of the major mechanisms of telomerase activation in gliomas. The unique pattern of TERT promoter mutations in relation to other genetic alterations suggests that they play distinct roles in the pathogenesis of oligodendroglial and astrocytic tumors. Our results shed a new light on the role of telomerase activation in the development of adult gliomas.
authors.affiliation: Department of Neurosurgery and Neuro-Oncology, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Arita
authors.forename: Yoshitaka
authors.initials: Y
authors.lastname: Narita
authors.forename: Shintaro
authors.initials: S
authors.lastname: Fukushima
authors.forename: Kensuke
authors.initials: K
authors.lastname: Tateishi
authors.forename: Yuko
authors.initials: Y
authors.lastname: Matsushita
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Yasuji
authors.initials: Y
authors.lastname: Miyakita
authors.forename: Makoto
authors.initials: M
authors.lastname: Ohno
authors.forename: V Peter
authors.initials: VP
authors.lastname: Collins
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Kawahara
authors.forename: Soichiro
authors.initials: S
authors.lastname: Shibui
authors.forename: Koichi
authors.initials: K
authors.lastname: Ichimura
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D045744:Cell Line, Tumor; D002878:Chromosomes, Human, Pair 1; D002888:Chromosomes, Human, Pair 19; D005260:Female; D005909:Glioblastoma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009837:Oligodendroglioma / Q000235:genetics* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011401:Promoter Regions, Genetic / Q000235:genetics; D016019:Survival Analysis; D019098:Telomerase / Q000235:genetics*; D014178:Translocation, Genetic / Q000235:genetics; D015854:Up-Regulation / Q000235:genetics
chemical_list: C509186:TERT protein, human; D019098:Telomerase